This company listing is no longer active
ASPC.Q Stock Overview
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men’s and women’s health.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Acerus Pharmaceuticals Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.22 |
52 Week High | US$7.42 |
52 Week Low | US$0.22 |
Beta | 0.47 |
11 Month Change | 0% |
3 Month Change | 0% |
1 Year Change | -97.23% |
33 Year Change | -96.76% |
5 Year Change | -99.60% |
Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Shareholder Returns
ASPC.Q | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | -2.7% | 0.9% |
1Y | -97.2% | 21.5% | 32.4% |
Return vs Industry: ASPC.Q underperformed the US Pharmaceuticals industry which returned -1.4% over the past year.
Return vs Market: ASPC.Q underperformed the US Market which returned -8.3% over the past year.
Price Volatility
ASPC.Q volatility | |
---|---|
ASPC.Q Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ASPC.Q has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ASPC.Q's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 14 | Ed Gudaitis | www.aceruspharma.com |
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men’s and women’s health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis.
Acerus Pharmaceuticals Corporation Fundamentals Summary
ASPC.Q fundamental statistics | |
---|---|
Market cap | US$1.69m |
Earnings (TTM) | -US$28.08m |
Revenue (TTM) | US$3.04m |
0.6x
P/S Ratio-0.1x
P/E RatioIs ASPC.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ASPC.Q income statement (TTM) | |
---|---|
Revenue | US$3.04m |
Cost of Revenue | US$1.33m |
Gross Profit | US$1.71m |
Other Expenses | US$29.79m |
Earnings | -US$28.08m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -3.64 |
Gross Margin | 56.32% |
Net Profit Margin | -924.33% |
Debt/Equity Ratio | -329.8% |
How did ASPC.Q perform over the long term?
See historical performance and comparison